Medically reviewed by Nicholas R. Metrus, MD Key Takeaways Headaches on the right side of the head could be migraines, ...

They arrive without warning and can leave people pacing, rocking, or clutching their heads in agony. Doctors call them cluster headaches, considered the most painful type of headache. According to the ...

Please provide your email address to receive an email when new articles are posted on . Approximately one in 1,000 people have cluster headaches. Cluster headaches are nicknamed “suicide headaches” ...

Migraine is a complex neurological disease that affects people in many different ways. But as painful and disabling as it can be, it's not the only headache disorder that can bring people to their ...

Women with cluster headache (CH) have more severe symptoms and longer headache bouts than men, and they are more likely to have a chronic subtype of the disorder, new research shows. The study, which ...

Galcanezumab (Emgality, Eli Lilly and Co), the humanized monoclonal antibody that targets calcitonin gene–related peptide (CGRP), provides consistent improvements over time for patients with episodic ...

Emgality is a monthly subcutaneous injection used to prevent episodic and chronic migraine. Migraine is a condition that causes intense throbbing or pulsating on one side of the head. Migraine may ...

You’ve been treating your recurring headaches as migraines for months or years, taking migraine medications and avoiding triggers that don’t seem to help. But many people who think they have migraines ...

Headaches are one of the most common medical conditions, with 96% of people having at least one in their lifetime, according to Cleveland Clinic. About 40% of people globally experience what are known ...

In a paper published in the May issue of JAMA, M. S. Robbins, of Weill Cornell Medical College, reviews the diagnosis, prevention, and treatment of primary headaches. In a previous post, I discussed ...

Eli Lilly secured federal approval for Emgality, the first migraine treatment approved in the U.S. for decreasing the frequency of episodic cluster headache attacks, the FDA announced June 4. 1.